Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design

2011 ◽  
Vol 17 (2) ◽  
pp. 365-375 ◽  
Author(s):  
Daphne M Hotho ◽  
Joep de Bruijne ◽  
A Marie O’Farrell ◽  
Teresa Boyea ◽  
Jianke Li ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Protease Inhibitor ◽  
Phase I ◽  
Study Design ◽  
Phase I Study ◽  
Hcv Protease

scholarly journals Workshop on phase I study design

1996 ◽  
Vol 7 (6) ◽  
pp. 567-573 ◽  
Author(s):  
S.G. Arbuck
Keyword(s):  
Phase I ◽  
Study Design ◽  
Phase I Study

A Phase-I Study of the Safety, Pharmacokinetics, and Antiviral Activity of Combination Didanosine and Ribavirin in Patients with HIV-1 Disease

1996 ◽  
Vol 13 (3) ◽  
pp. 235-246 ◽  
Author(s):  
Anthony J. Japour ◽  
Juan J. Lertora ◽  
Patricia M. Meehan ◽  
Alejo Erice ◽  
James D. Connor ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Phase I ◽  
Phase I Study ◽  
Hiv 1

scholarly journals Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2′-C-Methylcytidine, the Active Component of Valopicitabine

2006 ◽  
Vol 50 (10) ◽  
pp. 3444-3446 ◽  
Author(s):  
Lotte Coelmont ◽  
Jan Paeshuyse ◽  
Marc P. Windisch ◽  
Erik De Clercq ◽  
Ralf Bartenschlager ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Activity ◽  
Protease Inhibitor ◽  
Nucleoside Analogue ◽  
Active Component ◽  
Pyrimidine Nucleoside ◽  
Virus Activity ◽  
Hcv Protease

ABSTRACT Ribavirin antagonizes the in vitro anti-hepatitis C virus (HCV) activity of the pyrimidine nucleoside analogue 2′-C-methylcytidine, the active component of the experimental anti-HCV drug valopicitabine. In contrast, the combination of ribavirin with either the purine nucleoside analogue 2′-C-methyladenosine or the HCV protease inhibitor VX-950 resulted in an additive antiviral activity. These findings may have implications when planning clinical studies with valopicitabine.

Study design and early result of a phase I study of SABR for early-stage glottic cancer

2018 ◽  
Vol 128 (11) ◽  
pp. 2560-2565 ◽  
Author(s):  
Tosol Yu ◽  
Chan Woo Wee ◽  
Noorie Choi ◽  
Hong-Gyun Wu ◽  
Hyun-Cheol Kang ◽  
...  
Keyword(s):  
Phase I ◽  
Early Result ◽  
Study Design ◽  
Phase I Study ◽  
Early Stage ◽  
Glottic Cancer

Industry Watch

2004 ◽  
Vol 08 (14) ◽  
pp. 764-778
Keyword(s):  
Clinical Trials ◽  
Protease Inhibitor ◽  
Phase I ◽  
Therapeutic Antibodies ◽  
Phase I Clinical Trials ◽  
Hcv Protease ◽  
Philippine Government ◽  
Aids Drugs

AustCancer Explores New Market. Australian Stocks Upsurge 24%. EvoGenix Joins Viventia Biotech to create Cancer Therapeutic Antibodies. Nitazoxanide Launched in India. Philippine Government Pushes Biotech. SII Participates in International Meningitis Vaccine Project. Cipla's Pre-qualified AIDS Drugs Lack Bioequivalence Proof. Oral SOU-001 Phase I Clinical Trials Commenced in UK. Chugai Expands Indications for Rocephin. Mitsubishi Pharma Markets Oral HCV Protease Inhibitor in Asia. Pacific Edge Forecasts Financial Boom from Japanese Funds.

23 THE TAP STUDY: A PHASE I STUDY DESIGN TO SCREEN FOR UNEXPECTED AND/OR SEVERE INTERACTION BETWEEN RADIATION AND SYSTEMIC AGENTS

2009 ◽  
Vol 92 ◽  
pp. S8
Author(s):  
A. Brade ◽  
J. Wan ◽  
C. Chung ◽  
B. Southwood ◽  
A. Jarvi ◽  
...  
Keyword(s):  
Phase I ◽  
Study Design ◽  
Phase I Study ◽  
Systemic Agents
Sign in / Sign up

Export Citation Format

Share Document